Region — International. Neutral scientific reference — not offered for sale here.

Set region

Explore Shop Tools Journal Trust

Explore  /  Semaglutide

Research reference — not for sale

Semaglutide

lead outcome

Type-2 diabetes glycemic control

grades vary by outcome ↓

Peptide

also called — semaglutide · GLP-1 receptor agonist · Ozempic (type-2 diabetes brand) · Wegovy (obesity brand) · Rybelsus (oral brand) · GLP-1-S

metabolictype-2 diabetesobesity / weightcardiovascular / kidney (all approved)

Reference entry — explicitly NOT a sellable lane. Semaglutide is a patented, FDA-approved blockbuster prescription drug; it cannot be sold here as a cosmetic or "research" peptide, and compounded copies are now largely prohibited (below). It sits in the register for reference and completeness — the highest-demand, least-sellable case in the whole space (dominated by pharma and medical authorities). No dosing published here.

In brief

Semaglutide is a GLP-1 receptor agonist and one of the most-prescribed medicines in the world — FDA-approved for type-2 diabetes (Ozempic), obesity (Wegovy) and oral T2D (Rybelsus), with expanded cardiovascular and kidney indications. Its efficacy rests on one of the largest Phase 3 programmes in modern medicine (grade A). The compounded version that flooded the market is now largely prohibited following the February-2025 shortage resolution.

Legal standing, by region

European Union

Approved / prescription

approved (EMA) as Ozempic / Wegovy / Rybelsus.

United States

Approved / prescription

FDA-approved across multiple indications (Novo Nordisk brands only). Compounding: the injection shortage was declared resolved on 21 Feb 2025; the 503A/503B compounder phase-out deadlines have passed, so compounded semaglutide is now largely prohibited (narrow patient-specific exceptions aside). Gray-market and counterfeit "semaglutide" is unapproved and a documented safety risk.

International

widely approved

widely approved.

Evidence, by outcome

How we grade →

An honest grade per outcome — drawn from the evidence, not any catalogue. Hype and undemonstrated marketing claims grade low.

OutcomeEvidence base · effectGrade

Type-2 diabetes glycemic control

—

SUSTAIN Phase 3; FDA-approved · Robust HbA1c reduction

Chronic weight management (obesity)

Effect wanes if stopped; GI tolerability

STEP Phase 3 (~15% subQ); OASIS (oral); FDA-approved · Substantial weight loss

Cardiovascular risk reduction

—

SELECT (Wegovy), SOUL (oral); FDA-approved · Reduced major CV events

Kidney (T2D + CKD)

—

FLOW; FDA-approved (2025) · Reduced eGFR decline / ESKD / CV death

Safety

GI effects (nausea/vomiting/diarrhea); labeled risks; requires clinical oversight

Large trials + post-marketing · Well-characterised

—

Disclosure

Vallydia sells its own cosmetic serums, and some ingredients graded here belong to the same categories as those products. Grades are drawn from the published evidence by the method we publish, and applied to our own ingredients on the same terms — our copper-peptide serum is graded no more kindly than the peptides it competes with. We disclose the interest so you can weigh it.

Trade names shown here (for example Matrixyl, Argireline, Syn-Ake) are the property of their respective owners and are used only to identify the ingredient under discussion. Their appearance implies no affiliation with, or endorsement by, the proprietor.

Evidence changes

Get notified if this changes

We track new research and update these grades as the evidence moves. Leave your email and we'll tell you if the evidence for Semaglutide changes - nothing else.

Identity

an acylated GLP-1 analog — a ~31-amino-acid peptide (< 40 aa → peptide) based on human GLP-1(7-37) with substitutions plus a C18 fatty-diacid chain that binds albumin, giving a long half-life (once-weekly injection; also an oral tablet formulation). It is marketed under the trade names Ozempic (type-2 diabetes), Wegovy (obesity/weight management) and Rybelsus (oral tablet).

Mechanism (as proposed)

a GLP-1 receptor agonist — enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite centrally → glycemic control and weight loss.

Related reading

See also (cosmetic): Skincare on GLP-1s — "Ozempic face". Rapid weight loss on this drug can drive visible facial changes (hollowing, laxity, lines); this is an appearance effect of fast weight loss, not a dosing or safety matter.

Chemical identifiers

Cross-reference identifiers for the authoritative external databases — not a recipe, and nothing about how to use it.

CAS910463-68-2

PubChem CID56843331

InChIKeyDLSWIYLPEUIQAV-CCUURXOWSA-N

via PubChem exact-name match (Semaglutide) · high confidence

Sources — 1 cited

01SUSTAIN, STEP, SELECT, FLOW, SOUL, OASIS Phase 3 programmes; FDA prescribing information (Ozempic/Wegovy/Rybelsus); FDA Declaratory Order resolving the semaglutide shortage (Feb 2025).

Updated 2026-07-13

Grades reflect the published evidence, not our interest. No dosing, reconstitution, or administration is published for research compounds — that restraint is deliberate.

Related compounds

Explore by goal

Metabolic →

Vallydia

A neutral reference and a lawful-lane shop. Information for those who seek it — never promotion.

Region — International

ExploreRegister The Register — full index Categories Trust & COA How we grade Open data Brands

ShopCosmetic peptides Journal Quizzes

TermsPrivacyCookiesReturnsShippingImprint

This site provides neutral scientific reference and sells only products lawful in your region. Nothing here is medical advice, a recommendation, or an offer to supply unapproved medicines. No dosing or administration is published for research compounds. Cosmetic peptides per Regulation (EC) 1223/2009. Unapproved injectable peptides are neither sold nor advertised in the EU (Directive 2001/83/EC, Title VIII). © 2026 Vallydia.